Lipid nanoparticles (LNPs ... the company that developed the LNPs used in the Pfizer-BioNTech mRNA vaccine against SARS-CoV-2. She says it soon became clear that LNPs worked even better as ...

A breakthrough in safely delivering therapeutic DNA to cells could transform treatment for millions suffering from common chronic diseases like heart disease, diabetes, and cancer. A new process ...

One avenue for new vaccine development is mucosal vaccines. In theory, dosing the vaccine directly into the respiratory tract allows for robust antibody and T-cell responses where SARS-CoV-2 generally ...

mRNA-encoded self-assembling enveloped virus-like particles presenting SARS-CoV-2 spike protein enhance immunity and ... he developed that combines features of mRNA and protein nanoparticle-based ...

The SARS-CoV-2 virus, like all biological material, is composed of proteins, lipids, nucleic acids, metabolites and other small molecules. Researchers are using -omics technologies (e.g. proteomics, ...

The door may now be open for additional challenges to patents covering mRNA vaccine technologies, paving the way for increased competition in the ...

Findings show potential for new lipid-based delivery formulations as a platform technology for immunizationPhiladelphia, PA, ...

Function-engineerable nanoparticles in combination with the advantageous effects of various functional lipid components enable achievement of enhanced blood stability, decreased toxicity and ...

3 In addition to mRNA vaccines, potent antibody responses can also be elicited by protein-based vaccines, such as the Novavax NVX-CoV2373 vaccine, that present the SARS-CoV-2 spike protein on the ...